Alcobra Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arcturus Therapeutics Holdings Inc (ARCT)
Arcturus Therapeutics Holdings Inc stock price live, this page displays NASDAQ ARCT stock exchange data. View the ARCT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Arcturus Therapeutics Holdings Inc real time stock price chart below.
What Is the Arcturus Therapeutics Holdings Inc Stock Price Today?
The Arcturus Therapeutics Holdings Inc stock price today is 14.88.
What Is the Stock Symbol for Arcturus Therapeutics Holdings Inc?
The stock symbol for Arcturus Therapeutics Holdings Inc is ""ARCT.""
What Stock Exchange Does Arcturus Therapeutics Holdings Inc Trade On?
Arcturus Therapeutics Holdings Inc is listed and trades on the NASDAQ stock exchange.
Is Arcturus Therapeutics Holdings Inc a Good Stock to Buy?
Determining whether Arcturus Therapeutics Holdings Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARCT quote. (ISIN: US03969T1097)
What Is the Arcturus Therapeutics Holdings Inc Stock Price Today?
The Arcturus Therapeutics Holdings Inc stock price today is 14.88.
What Is the Stock Symbol for Arcturus Therapeutics Holdings Inc?
The stock symbol for Arcturus Therapeutics Holdings Inc is ""ARCT.""
What Stock Exchange Does Arcturus Therapeutics Holdings Inc Trade On?
Arcturus Therapeutics Holdings Inc is listed and trades on the NASDAQ stock exchange.
Is Arcturus Therapeutics Holdings Inc a Good Stock to Buy?
Determining whether Arcturus Therapeutics Holdings Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARCT quote. (ISIN: US03969T1097)
14.88
-0.57(-3.72%)
Real-time Data·
Fair Value
An estimate of a Arcturus Therapeutics Holdings Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.86
15.50
52 wk Range
8.04
25.88
ARCT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ARCT is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Arcturus Therapeutics Holdings Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.8615.50
52 wk Range
8.0425.88
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ARCT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Arcturus Therapeutics Holdings Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
67.40
Upside
+352.96%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings upwards for the upcoming period
- Alcobra Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Alcobra Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Arcturus Therapeutics Holdings Inc Company Profile
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Arcturus Therapeutics Holdings Inc SWOT Analysis
mRNA Trailblaze | Arcturus Therapeutics leads with self-amplifying mRNA technology, potentially revolutionizing vaccine efficacy and safety profiles in a competitive market |
Financial Trajectory | Explore Arcturus' path to profitability, balancing strong liquidity with negative margins as it aims to capitalize on its innovative pipeline |
Strategic Alliances | Delve into Arcturus' partnership with CSL Seqirus, offering billions in potential milestones and global market access for its vaccine candidates |
Market Opportunities | Analyst targets range from $41 to $140, reflecting diverse views on Arcturus' potential in COVID-19, influenza, and emerging vaccine markets |
Arcturus Therapeutics Holdings Inc Earnings Call Summary for Q1/2025
- Q1 2025 revenue fell to $29.4M, missing $205.21M forecast; EPS loss of $0.52 vs expected $3.59 profit
- Stock surged 9.84% in after-hours trading despite earnings miss; market cap at $313.51M
- Cash runway extended to Q1 2028; R&D expenses decreased to $34.9M from $53.6M year-over-year
- Focus remains on mRNA therapeutics pipeline; multiple clinical data sets expected in 2025
- No significant U.S. milestones anticipated until 2028; ongoing investments in therapeutic pipeline projected
Last Updated: 12/05/2025, 22:28
Read Full TranscriptCompare ARCT to Peers and Sector
Metrics to compare | ARCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARCTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.1x | −3.7x | −0.5x | |
PEG Ratio | −0.16 | −0.10 | 0.00 | |
Price/Book | 1.8x | 1.1x | 2.6x | |
Price / LTM Sales | 2.9x | 10.8x | 3.2x | |
Upside (Analyst Target) | 264.7% | 90.0% | 41.9% | |
Fair Value Upside | Unlock | 15.0% | 4.3% | Unlock |
Analyst Ratings
11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 67.40
(+352.96% Upside)
Earnings
Latest Release
May 12, 2025
EPS / Forecast
-0.52 / 3.59
Revenue / Forecast
29.38M / 205.21M
People Also Watch
FAQ
What Stock Exchange Does Arcturus Therapeutics Holdings Inc Trade On?
Arcturus Therapeutics Holdings Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Arcturus Therapeutics Holdings Inc?
The stock symbol for Arcturus Therapeutics Holdings Inc is "ARCT."
What Is the Arcturus Therapeutics Holdings Inc Market Cap?
As of today, Arcturus Therapeutics Holdings Inc market cap is 405.18M.
What Is Arcturus Therapeutics Holdings Inc's Earnings Per Share (TTM)?
The Arcturus Therapeutics Holdings Inc EPS (TTM) is -2.52.
When Is the Next Arcturus Therapeutics Holdings Inc Earnings Date?
Arcturus Therapeutics Holdings Inc will release its next earnings report on 10 Aug 2025.
From a Technical Analysis Perspective, Is ARCT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Arcturus Therapeutics Holdings Inc Stock Split?
Arcturus Therapeutics Holdings Inc has split 1 times.
How Many Employees Does Arcturus Therapeutics Holdings Inc Have?
Arcturus Therapeutics Holdings Inc has 175 employees.
What is the current trading status of Arcturus Therapeutics Holdings Inc (ARCT)?
As of 24 Jul 2025, Arcturus Therapeutics Holdings Inc (ARCT) is trading at a price of 14.88, with a previous close of 15.45. The stock has fluctuated within a day range of 14.86 to 15.50, while its 52-week range spans from 8.04 to 25.88.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.